Riley D. Bowers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Riley D. Bowers has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Carrie Baker
Cape Fear Valley Medical Center, Fayetteville, NC, USA
7 shared publications - Marcus Mize
Pharmacy, Wingate University Levine College of Health Sciences
3 shared publications - Jeremy Hughes
University of Washington School of Pharmacy
2 shared publications - Jonathan Thigpen
Samford University McWhorter School of Pharmacy
2 shared publications - Katie Trotta
Campbell University College of Pharmacy & Health Sciences, PO Box 1090, Buies Creek, NC 27506, USA
2 shared publications Scott L. Perkins
Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA
2 shared publications
Latest Publications
- 26 October 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
Dose-Reduced Apixaban for Thromboembolism in a Patient With Obesity on Cobicistat: A Case Report
Background/Objective: Current guidelines recommend a 50% dose reduction of apixaban for patients receiving strong CYP3A4/P-glycoprotein (P-gp) inhibitors regardless of body habitus. However, evidence supporting this dose adjustment in patients with severe obesity (BMI >40 kg/m 2 ) is limited. This report describes the use of dose-reduced apixaban for the treatment of venous thromboembolism in a patient with a BMI >50 kg/m 2 receiving a strong CYP3A4/P-gp inhibitor. Summary: A 38-year-old female with a BMI of 81.71 kg/m 2 and a history of HIV on a cobicistat-containing antiretroviral regimen was diagnosed with a left femoral deep vein thromboembolism. She was initially treated with warfarin and enoxaparin bridge therapy but was transitioned to apixaban prior to discharge. Apixaban was initiated at a 50% dose reduction due to the concomitant use of cobicistat, a strong CYP3A4/P-gp inhibitor. The patient successfully completed therapy without recurrence of thromboembolism or bleeding complications. Conclusion: This case demonstrates the successful use of dose-reduced apixaban in a patient with a BMI >50 kg/m 2 receiving a CYP3A4/P-gp inhibitor for the treatment of venous thromboembolism and adds to available literature on apixaban dosing in patients with obesity.
- 26 October 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
Dose-Reduced Apixaban for Thromboembolism in a Patient With Obesity on Cobicistat: A Case Report
Background/Objective: Current guidelines recommend a 50% dose reduction of apixaban for patients receiving strong CYP3A4/P-glycoprotein (P-gp) inhibitors regardless of body habitus. However, evidence supporting this dose adjustment in patients with severe obesity (BMI >40 kg/m 2 ) is limited. This report describes the use of dose-reduced apixaban for the treatment of venous thromboembolism in a patient with a BMI >50 kg/m 2 receiving a strong CYP3A4/P-gp inhibitor. Summary: A 38-year-old female with a BMI of 81.71 kg/m 2 and a history of HIV on a cobicistat-containing antiretroviral regimen was diagnosed with a left femoral deep vein thromboembolism. She was initially treated with warfarin and enoxaparin bridge therapy but was transitioned to apixaban prior to discharge. Apixaban was initiated at a 50% dose reduction due to the concomitant use of cobicistat, a strong CYP3A4/P-gp inhibitor. The patient successfully completed therapy without recurrence of thromboembolism or bleeding complications. Conclusion: This case demonstrates the successful use of dose-reduced apixaban in a patient with a BMI >50 kg/m 2 receiving a CYP3A4/P-gp inhibitor for the treatment of venous thromboembolism and adds to available literature on apixaban dosing in patients with obesity.
- 21 August 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
Factors Influencing Post-Residency Career Choices Among Graduating PGY1 Pharmacy Residents
Purpose: To examine factors that influence the post-residency decision-making process of PGY1 pharmacy residents. Methods: An eleven-question survey was disseminated to individuals who completed a PGY1 residency in the past 5 years (2019-2023). The primary outcome was the most common factors that influenced PGY1 residents to choose either a PGY2 residency or employment after graduation. Factors evaluated included finances, family obligations, clinical experience, burnout, and career opportunities. Only fully completed surveys were included in analyses. Results: A total of 135 participants completed the survey. Response rate from all possible PGY1 graduates was 1.3%, with a response rate of 50.6% of those who clicked the distributed survey link. Of the 135 responses, 89 (66%) pursued PGY2 residency, while 46 (34%) pursued employment. Of those pursuing PGY2, desire to specialize, clinical experience, and career opportunities were the top 3 factors influencing their decision. Those choosing employment reported well-being/burnout, career opportunities, and job outlook as their top 3 most influential factors. Statistically significant differences were observed regarding the influence of 7 (64%) factors contributing to deciding between pursuing a PGY2 residency or employment, although some, including convenience and competitiveness of a specialty, had low scores on overall influence. Conclusion: Many factors influence post-PGY1 career decision with desire to specialize being the most influential factor among those pursuing PGY2, while well-being/burnout was the most influential factor among those pursuing employment. By identifying these factors, the study contributes to a deeper understanding of resident preferences and informs strategies to optimize pharmacy education and training programs.
- 21 August 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
Factors Influencing Post-Residency Career Choices Among Graduating PGY1 Pharmacy Residents
Purpose: To examine factors that influence the post-residency decision-making process of PGY1 pharmacy residents. Methods: An eleven-question survey was disseminated to individuals who completed a PGY1 residency in the past 5 years (2019-2023). The primary outcome was the most common factors that influenced PGY1 residents to choose either a PGY2 residency or employment after graduation. Factors evaluated included finances, family obligations, clinical experience, burnout, and career opportunities. Only fully completed surveys were included in analyses. Results: A total of 135 participants completed the survey. Response rate from all possible PGY1 graduates was 1.3%, with a response rate of 50.6% of those who clicked the distributed survey link. Of the 135 responses, 89 (66%) pursued PGY2 residency, while 46 (34%) pursued employment. Of those pursuing PGY2, desire to specialize, clinical experience, and career opportunities were the top 3 factors influencing their decision. Those choosing employment reported well-being/burnout, career opportunities, and job outlook as their top 3 most influential factors. Statistically significant differences were observed regarding the influence of 7 (64%) factors contributing to deciding between pursuing a PGY2 residency or employment, although some, including convenience and competitiveness of a specialty, had low scores on overall influence. Conclusion: Many factors influence post-PGY1 career decision with desire to specialize being the most influential factor among those pursuing PGY2, while well-being/burnout was the most influential factor among those pursuing employment. By identifying these factors, the study contributes to a deeper understanding of resident preferences and informs strategies to optimize pharmacy education and training programs.
- 19 September 2024
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 38 (2) , 270-274
Very High Warfarin Dosing Requirements in a Patient With Tuberculosis and a Pulmonary Embolism: A Case Report
Purpose: To describe a case of significantly increased warfarin requirements in a patient receiving rifampin for the management of tuberculosis. Summary: A 76-year-old male was admitted due to altered mentation, cough, and weight loss. He was diagnosed concurrently with tuberculosis and a pulmonary embolism. Given the profound effect of rifampin on CYP450 enzymes, direct oral anticoagulants were avoided and warfarin therapy was selected. Management was further complicated by a gastrointestinal bleed during admission, history of cancer, and low body weight. After several weeks of daily international normalized ratio monitoring, a stable regimen of 14 mg of warfarin daily was established, allowing for the patient’s safe discharge. Practice Implications: This report underscores the significance of tailored treatment plans, vigilant monitoring, and interdisciplinary collaboration which are necessary to navigate the complexities associated with these medications and optimize patient outcomes.
- 19 September 2024
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 38 (2) , 270-274
Very High Warfarin Dosing Requirements in a Patient With Tuberculosis and a Pulmonary Embolism: A Case Report
Purpose: To describe a case of significantly increased warfarin requirements in a patient receiving rifampin for the management of tuberculosis. Summary: A 76-year-old male was admitted due to altered mentation, cough, and weight loss. He was diagnosed concurrently with tuberculosis and a pulmonary embolism. Given the profound effect of rifampin on CYP450 enzymes, direct oral anticoagulants were avoided and warfarin therapy was selected. Management was further complicated by a gastrointestinal bleed during admission, history of cancer, and low body weight. After several weeks of daily international normalized ratio monitoring, a stable regimen of 14 mg of warfarin daily was established, allowing for the patient’s safe discharge. Practice Implications: This report underscores the significance of tailored treatment plans, vigilant monitoring, and interdisciplinary collaboration which are necessary to navigate the complexities associated with these medications and optimize patient outcomes.
- 31 July 2024
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 16 (11) , 102159
Comparison of peer, self, and faculty objective structured clinical examination evaluations in a PharmD nonprescription therapeutics course
- 31 July 2024
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 16 (11) , 102159
Comparison of peer, self, and faculty objective structured clinical examination evaluations in a PharmD nonprescription therapeutics course
- 7 May 2024
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 88 (6) , 100708
The Role of Consumerism in Pharmacy Education
- 7 May 2024
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 88 (6) , 100708
The Role of Consumerism in Pharmacy Education
- 12 January 2024
- Published by International Pharmaceutical Federation (FIP) in Pharmacy Education
- Vol. 24 (1) , 730-738
Reliability of a modified single-point rubric for assessment of integrated pharmacotherapy cases
Background: The Pharmacists’ Patient Care Process (PPCP) offers a method to integrate pharmacotherapy cases between disciplines. However, establishing a consistent grading standard across multiple faculty and disciplines creates a challenge. The purpose of this study was to describe the reliability of a single-point rubric for assessing integrated cases among interdisciplinary graders. Methods: A single-point rubric was developed to provide students with formative and summative feedback on existing integrated cases requiring written PPCP notes. The rubric was calibrated retrospectively on a sample of deidentified cases from two integrated pharmacotherapy courses. Following calibration, 20 submissions were evaluated by an interdisciplinary team of faculty. The following year, four new evaluators graded 12 submissions to ensure continued reliability. Results: Fleiss' kappa was used to determine if there was an agreement between instructors’ judgement on the final grade classification of the original 20 submissions. There was almost perfect agreement between the instructors’ judgements, κ= .868. Each section of the PPCP and overall numerical score all showed significant agreement using Kendall’s W. Results were similar the following year with four new graders. Conclusion: This study demonstrates the continued reliability of a modified single-point rubric to evaluate written cases involving multiple disciplines.
- 12 January 2024
- Published by International Pharmaceutical Federation (FIP) in Pharmacy Education
- Vol. 24 (1) , 730-738
Reliability of a modified single-point rubric for assessment of integrated pharmacotherapy cases
Background: The Pharmacists’ Patient Care Process (PPCP) offers a method to integrate pharmacotherapy cases between disciplines. However, establishing a consistent grading standard across multiple faculty and disciplines creates a challenge. The purpose of this study was to describe the reliability of a single-point rubric for assessing integrated cases among interdisciplinary graders. Methods: A single-point rubric was developed to provide students with formative and summative feedback on existing integrated cases requiring written PPCP notes. The rubric was calibrated retrospectively on a sample of deidentified cases from two integrated pharmacotherapy courses. Following calibration, 20 submissions were evaluated by an interdisciplinary team of faculty. The following year, four new evaluators graded 12 submissions to ensure continued reliability. Results: Fleiss' kappa was used to determine if there was an agreement between instructors’ judgement on the final grade classification of the original 20 submissions. There was almost perfect agreement between the instructors’ judgements, κ= .868. Each section of the PPCP and overall numerical score all showed significant agreement using Kendall’s W. Results were similar the following year with four new graders. Conclusion: This study demonstrates the continued reliability of a modified single-point rubric to evaluate written cases involving multiple disciplines.
- Open Access
- 18 August 2023
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 87 (8) , 100141
ALFP Cohort 19 Debate and AACP Award Poster Abstracts Presented at the 124th Annual Meeting of the American Association of Colleges of Pharmacy, July 22-25, 2023
- 18 August 2023
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 87 (8) , 100141
Open AccessALFP Cohort 19 Debate and AACP Award Poster Abstracts Presented at the 124th Annual Meeting of the American Association of Colleges of Pharmacy, July 22-25, 2023
- 7 December 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (2) , 517-521
Reduced-Dose Apixaban in the Treatment of Left Ventricular Thrombus: A Report of 2 Cases
According to the American College of Cardiology and the American Heart Association, warfarin has historically been the standard of care anticoagulant for the treatment of left ventricular thrombus. The use of direct oral anticoagulants (DOACs) has become more prevalent, as they require less frequent laboratory monitoring, offer fixed-dose regimens, are associated with fewer drug-drug and drug-food interactions, and provide more favorable safety profiles when compared to warfarin. However, DOACs are not currently FDA-indicated in the treatment of left ventricular (LV) thrombus. Numerous recent studies have reported and evaluated the use of DOACs for treatment of LV thrombus. Recently, a prospective, open-label, multicenter study evaluated warfarin compared to DOACs for LV thrombus treatment. The AHA recently published a scientific statement regarding the management of patients at risk for and with left ventricular thrombus, which included DOACs as a reasonable alternative to warfarin. This report describes two patients treated with DOACs following LV thrombus diagnosis. The first case is a 71-year-old male admitted for cerebrovascular accident and non-ST-elevation myocardial infarction complicated by a LV thrombus. The second case is an 83-year-old female admitted for acute myocardial infarction complicated with an LV thrombus. Both patients were prescribed apixaban 2.5 mg twice daily. Neither patient has experienced LV thrombus or DOAC treatment related complications. This case series serves as evidence for reduced-dose DOACs as an alternative to warfarin in the treatment of LV thrombus.
- 7 December 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (2) , 517-521
Reduced-Dose Apixaban in the Treatment of Left Ventricular Thrombus: A Report of 2 Cases
According to the American College of Cardiology and the American Heart Association, warfarin has historically been the standard of care anticoagulant for the treatment of left ventricular thrombus. The use of direct oral anticoagulants (DOACs) has become more prevalent, as they require less frequent laboratory monitoring, offer fixed-dose regimens, are associated with fewer drug-drug and drug-food interactions, and provide more favorable safety profiles when compared to warfarin. However, DOACs are not currently FDA-indicated in the treatment of left ventricular (LV) thrombus. Numerous recent studies have reported and evaluated the use of DOACs for treatment of LV thrombus. Recently, a prospective, open-label, multicenter study evaluated warfarin compared to DOACs for LV thrombus treatment. The AHA recently published a scientific statement regarding the management of patients at risk for and with left ventricular thrombus, which included DOACs as a reasonable alternative to warfarin. This report describes two patients treated with DOACs following LV thrombus diagnosis. The first case is a 71-year-old male admitted for cerebrovascular accident and non-ST-elevation myocardial infarction complicated by a LV thrombus. The second case is an 83-year-old female admitted for acute myocardial infarction complicated with an LV thrombus. Both patients were prescribed apixaban 2.5 mg twice daily. Neither patient has experienced LV thrombus or DOAC treatment related complications. This case series serves as evidence for reduced-dose DOACs as an alternative to warfarin in the treatment of LV thrombus.
- Open Access
- 1 November 2022
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 86 (8) , ajpe8857
Comparison of Student Pharmacists’ Knowledge Retention Utilizing Electronic Health Records Versus Simultaneously Completing Simulated Experiences
Objective. Interprofessional team-based care has become the standard for practicing clinical pharmacists. However, it is difficult to simulate every aspect of this environment in the didactic curriculum. The purpose of this study was to determine if the addition of standardized patients (SP) or interprofessional student teams with SPs, to the use of a simulated electronic health record (EHR) improved student knowledge retention and perceptions. Methods. This was a prospective cohort study assessing three cohorts of first-year student pharmacists in pharmacy skills laboratory activities that occurred in 2018, 2019, and 2021. The primary objective of the study was to compare knowledge retention at 1-month related to the case material between groups. Each year an element of simulated experience was added onto the previous year’s case. In 2018, students completed the case using the EHR web application only. In 2019, an objective structured clinical examination (OSCE) with SPs was combined with the previous year’s experience. In 2021, student physician assistants were added to the 2019 experience. Case scores and student perceptions were also compared between groups. Results. Of the 260 potential participants, 238 students were included in the primary analysis. Significant improvement was demonstrated in one-month knowledge retention assessments with the addition of interprofessional team-based care and SPs. Mean knowledge retention assessment scores were 63.8%, 71.7%, and 76.1% respectively. There was also significant improvement in student perceptions. Conclusion. The addition of SPs and interprofessional team-based care to a pharmacy skills laboratory that utilizes a simulated EHR significantly improved student knowledge retention and perceptions.
- 1 November 2022
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 86 (8) , ajpe8857
Open AccessComparison of Student Pharmacists’ Knowledge Retention Utilizing Electronic Health Records Versus Simultaneously Completing Simulated Experiences
Objective. Interprofessional team-based care has become the standard for practicing clinical pharmacists. However, it is difficult to simulate every aspect of this environment in the didactic curriculum. The purpose of this study was to determine if the addition of standardized patients (SP) or interprofessional student teams with SPs, to the use of a simulated electronic health record (EHR) improved student knowledge retention and perceptions. Methods. This was a prospective cohort study assessing three cohorts of first-year student pharmacists in pharmacy skills laboratory activities that occurred in 2018, 2019, and 2021. The primary objective of the study was to compare knowledge retention at 1-month related to the case material between groups. Each year an element of simulated experience was added onto the previous year’s case. In 2018, students completed the case using the EHR web application only. In 2019, an objective structured clinical examination (OSCE) with SPs was combined with the previous year’s experience. In 2021, student physician assistants were added to the 2019 experience. Case scores and student perceptions were also compared between groups. Results. Of the 260 potential participants, 238 students were included in the primary analysis. Significant improvement was demonstrated in one-month knowledge retention assessments with the addition of interprofessional team-based care and SPs. Mean knowledge retention assessment scores were 63.8%, 71.7%, and 76.1% respectively. There was also significant improvement in student perceptions. Conclusion. The addition of SPs and interprofessional team-based care to a pharmacy skills laboratory that utilizes a simulated EHR significantly improved student knowledge retention and perceptions.
- 1 July 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (4) , S6-S10.e2
Identifying barriers to utilization of a medication access program among referred patients surveyed after discharge from an acute care hospital
- 1 July 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (4) , S6-S10.e2
Identifying barriers to utilization of a medication access program among referred patients surveyed after discharge from an acute care hospital